| Autor: |
Mahoney, Donald H, Yu, Ariel, Stewart, Chip, Costello, Joseph F, Stine, Kimo C, Stieglitz, Elliot, Cooper, Todd, Liu, Y Lucy, Olshen, Adam B, Gerbing, Robert B, Goyal, Rakesh K, Hugge, Christopher, Beckman, Kyle, Brown, Patrick A, Toretsky, Jeffrey A, Briones, Michael, Ma, Jing, Nemecek, Eneida R, Roehrs, Philip A, Abusin, Ghada, Schore, Reuven J, Hitzler, Johann, Li, Yongjin, Hayashi, Robert J, Monteleone, Philip, Carcamo, Benjamin, Emanuel, Peter D, Messinger, Yoav H, Archambeault, Sophie L, Takemoto, Clifford M, Fluchel, Mark N, Dahl, Gary V |
| Jazyk: |
angličtina |
| Rok vydání: |
2015 |
| DOI: |
10.17615/mrye-5404 |
| Popis: |
Juvenile myelomonocytic leukemia (JMML) is a myeloproliferative neoplasm (MPN) of childhood with a poor prognosis. Mutations in NF1, NRAS, KRAS, PTPN11 and CBL occur in 85% of patients, yet there are currently no risk stratification algorithms capable of predicting which patients will be refractory to conventional treatment and therefore be candidates for experimental therapies. In addition, there have been few other molecular pathways identified aside from the Ras/MAPK pathway to serve as the basis for such novel therapeutic strategies. We therefore sought to genomically characterize serial samples from patients at diagnosis through relapse and transformation to acute myeloid leukemia in order to expand our knowledge of the mutational spectrum in JMML. We identified recurrent mutations in genes involved in signal transduction, gene splicing, the polycomb repressive complex 2 (PRC2) and transcription. Importantly, the number of somatic alterations present at diagnosis appears to be the major determinant of outcome. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
